0001437749-24-012586.txt : 20240419 0001437749-24-012586.hdr.sgml : 20240419 20240419172154 ACCESSION NUMBER: 0001437749-24-012586 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240418 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240419 DATE AS OF CHANGE: 20240419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NovaBay Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001389545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 680454536 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33678 FILM NUMBER: 24858964 BUSINESS ADDRESS: STREET 1: 2000 POWELL STREET, SUITE 1150 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: (510) 899-8800 MAIL ADDRESS: STREET 1: 2000 POWELL STREET, SUITE 1150 CITY: EMERYVILLE STATE: CA ZIP: 94608 8-K 1 nby20240419_8k.htm FORM 8-K nby20240419_8k.htm
false 0001389545 0001389545 2024-04-18 2024-04-18
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of earliest event reported: April 18, 2024
 
NovaBay Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
001-33678
68-0454536
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(I.R.S. Employer
Identification No.)
 
2000 Powell Street, Suite 1150, Emeryville, CA 94608
(Address of Principal Executive Offices) (Zip Code)
 
(510) 899-8800
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of Each Class
  
Trading Symbol(s)
  
Name of Each Exchange On Which
Registered
Common Stock, par value $0.01 per share
  
NBY
  
NYSE American
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
 
On April 18, 2024, NovaBay Pharmaceuticals, Inc. (the “Company”) received a notification (“Deficiency Letter”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”) requiring stockholders’ equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively.
 
Pursuant to the Deficiency Letter, the Company has become subject to the procedures and requirements of Section 1009 of the Company Guide and must submit a plan of compliance by May 18, 2024 addressing how it intends to regain compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide by October 18, 2025. As of December 31, 2023, the Company had stockholders’ equity of $3.3 million.
 
The Company intends to submit a plan to regain compliance with NYSE American listing standards. If the Company does not regain compliance with those standards, or does not make progress consistent with the plan, the NYSE American staff may commence delisting proceedings. The Deficiency Letter has no immediate effect on the listing or trading of the Company’s common stock, and the Company’s common stock will continue to trade on the NYSE American under the symbol “NBY”, although a “below compliance” indicator will appended to the Company’s ticker symbol (with the added designation of “.BC”) during the period the Company is not in compliance with the NYSE American’s continued listing standards. The Company’s receipt of the Deficiency Letter does not affect the Company’s business operations or its reporting requirements with the Securities and Exchange Commission (“SEC”).
 
Item 8.01
Other Events
 
On April 19, 2024, the Company issued a press release announcing its receipt of the Deficiency Letter. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.
 
Forward-Looking Statements
 
This report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the impact of the Deficiency Letter and the Company’s ability to comply with the continued listing requirements of the NYSE American. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Other risks relating to the Company’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this report, are detailed in the Company’s latest Form 10-K filing with the SEC, especially under the heading “Risk Factors,” and in the definitive proxy statement filed by NovaBay with the SEC, especially under the heading “Proposal Five: The Reverse Stock Split Proposal — Risks Relating to the Reverse Stock Split.” The forward-looking statements in this report speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
 
Item 9.01
Financial Statements and Exhibits.
 
(d)
Exhibits.
 
Exhibit
No.
  
Description
99.1
  
104
  
Cover Page Interactive Date File (embedded with the Inline XBRL document)
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
NovaBay Pharmaceuticals, Inc.
  
 
By:
/s/ Justin Hall
  
   
Justin Hall
  
   
Chief Executive Officer and General Counsel
  
 
Dated: April 19, 2024
 
 
 EX-99.1 2 ex_657264.htm EXHIBIT 99.1 ex_657264.htm

Exhibit 99.1

 

nb01.jpg
 

NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity

 

EMERYVILLE, Calif. (April 19, 2024) – NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide pursuant to stockholders equity. The Company must submit a plan by May 18, 2024 advising of actions it has taken or will take to regain compliance with the continued listing standards by October 18, 2025 in order to continue its listing on the NYSE American.

 

The Company intends to submit a plan to regain compliance to the NYSE American within the prescribed timeframe. The notice from the NYSE American has no immediate effect on the listing or trading of the Company’s common stock, and the common stock will continue to trade on the NYSE American. The notice does not affect the Company’s ongoing business operations or its reporting requirements with the Securities and Exchange Commission (SEC).

 

About NovaBay Pharmaceuticals, Inc.

NovaBay’s leading product Avenova® Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is available directly to consumers through online distribution channels such as Amazon.com. It is clinically proven to kill a broad spectrum of bacteria to help relieve the symptoms of bacterial dry eye, yet is non-irritating and completely safe for regular use. NovaBay offers a full portfolio of scientifically developed products for each step of the standard dry eye treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, Avenova Warm Eye Compress to soothe the eyes and the i-Chek by Avenova to monitor physical eyelid health. The Avenova Allograft, an amniotic tissue prescription-only product, is available through eyecare professionals in the United States.

 

NovaBay Pharmaceuticals Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company’s ability to regain compliance with the continued listing requirements of the NYSE American. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K filing with the SEC, especially under the heading “Risk Factors,” and in the definitive proxy statement filed by NovaBay with the SEC, especially under the heading “Proposal Five: The Reverse Stock Split Proposal — Risks Relating to the Reverse Stock Split.” The forward-looking statements in this press release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

 

 
 

 

Socialize and Stay Informed on NovaBay’s Progress

Like us on Facebook

Follow us on X

Connect with NovaBay on LinkedIn

Visit NovaBay’s Website

 

Avenova Purchasing Information

For NovaBay Avenova purchasing information:

Please call 800-890-0329 or email sales@avenova.com

Avenova.com

 

NovaBay Contact

Justin Hall

Chief Executive Officer and General Counsel

510-899-8800

jhall@novabay.com

 

Investor Contact

LHA Investor Relations

Jody Cain

310-691-7100
jcain@lhai.com

 

# # #

 

 
 EX-101.SCH 3 nby-20240418.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 nby-20240418_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 nby-20240418_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 nby-20240418_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 nb01.jpg begin 644 nb01.jpg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htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document And Entity Information
Apr. 18, 2024
Document Information [Line Items]  
Entity, Registrant Name NovaBay Pharmaceuticals, Inc.
Document, Type 8-K
Document, Period End Date Apr. 18, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-33678
Entity, Tax Identification Number 68-0454536
Entity, Address, Address Line One 2000 Powell Street, Suite 1150
Entity, Address, City or Town Emeryville
Entity, Address, State or Province CA
Entity, Address, Postal Zip Code 94608
City Area Code 510
Local Phone Number 899-8800
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol NBY
Security Exchange Name NYSE
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001389545
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.nby.com/20240418/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports nby-20240418.xsd nby-20240418_def.xml nby-20240418_lab.xml nby-20240418_pre.xml nby20240419_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nby20240419_8k.htm": { "nsprefix": "nby", "nsuri": "http://www.nby.com/20240418", "dts": { "schema": { "local": [ "nby-20240418.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "nby-20240418_def.xml" ] }, "labelLink": { "local": [ "nby-20240418_lab.xml" ] }, "presentationLink": { "local": [ "nby-20240418_pre.xml" ] }, "inline": { "local": [ "nby20240419_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.nby.com/20240418/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20240419_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "nby20240419_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.nby.com/20240418/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001437749-24-012586-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-012586-xbrl.zip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end XML 19 nby20240419_8k_htm.xml IDEA: XBRL DOCUMENT 0001389545 2024-04-18 2024-04-18 false 0001389545 8-K 2024-04-18 NovaBay Pharmaceuticals, Inc. DE 001-33678 68-0454536 2000 Powell Street, Suite 1150 Emeryville CA 94608 510 899-8800 false false false false Common Stock NBY NYSE false